Checkpoint kinase inhibitor azd7762overcomescisplatin resistance in clear cell carcinoma of the ovary

International Journal of Gynecological Cancer

Volumn 24, Issue 1, 2014, Pages 61-69

  Itamochi, Hiroaki ^a   Nishimura, Mayumi ^b   Oumi, Nao ^b   Kato, Misaki ^b   Oishi, Tetsuro ^a   Shimada, Muneaki ^a   Sato, Shinya ^a   Naniwa, Jun ^a   Sato, Seiya ^a   Kudoh, Akiko ^a   Kigawa, Junzo ^b   Harada, Tasuku ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Checkpoint kinase; Cisplatin; Clear cell; Ovarian carcinoma; Resistance

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; CASPASE 9; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; FIRTECAN; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CELLULAR DISTRIBUTION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; THIOPHENES; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893692034     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000014     Document Type: Article

References (28)

1. Scully RE. World Health Organization classification and nomenclature of ovarian cancer. Natl Cancer Inst Monogr. 1975;42:5-7.
2. Aure JC, Hoeg K, Kolstad P. Mesonephroid tumors of the ovary. Clinical and histopathologic studies. Obstet Gynecol. 1971;37:860-867.
3. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
4. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008;99:653-658.
5. Itamochi H, Kigawa J, Akeshima R, et al. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology. 2002;62:349-353.
6. Itamochi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 2002;100: 281-287.
7. Itamochi H, Yoshida T, Walker CL, et al. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011;122:641-647.
8. Nonaka M, Itamochi H, Kawaguchi W, et al. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells. Int J Gynecol Cancer. 2012;22:922-929.
9. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265-7279.
10. Ashwell S, Zabludoff S. DNA damage detection and repair pathwaysVrecent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res. 2008;14:4032-4037.
11. Oza V, Ashwell S, Almeida L, et al. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl) -3-ureidothiophene-2- carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas. J Med Chem. 2012;55: 5130-5142.
12. Zabludoff SD, Deng C, Grondine MR, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008;7:2955-2966.
13. Bartucci M, Svensson S, Romania P, et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ. 2012;19:768-778.
14. Mitchell JB, Choudhuri R, Fabre K, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res. 2010;16:2076-2084.
15. Parsels LA, Qian Y, Tanska DM, et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res. 2011;17:3706-3715.
16. Itamochi H, Kato M, Nishimura M, et al. Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. Hum Cell. 2013;26:121-127.
17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
18. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421-429.
19. Mailand N, Falck J, Lukas C, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science. 2000;288:1425-1429.
20. Parsels LA, Morgan MA, Tanska DM, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther. 2009;8:45-54.
21. Carrassa L, Broggini M, Erba E, et al. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle. 2004;3:1177-1181.
22. Morgan MA, Parsels LA, Parsels JD, et al. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle. 2006;5:1983-1988.
23. Blasina A, Hallin J, Chen E, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther. 2008;7:2394-2404.
24. Jobson AG, Lountos GT, Lorenzi PL, et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther. 2009;331:816-826.
25. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 2010;16:376-383.
26. Enders GH. Expanded roles for Chk1 in genome maintenance. J Biol Chem. 2008;283:17749-17752.
27. Antoni L, Sodha N, Collins I, et al. CHK2 kinase: cancer susceptibility and cancer therapyVtwo sides of the same coin? Nat Rev Cancer. 2007;7:925-936.
28. Stolz A, Ertych N, Bastians H. Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res. 2011;17: 401-405.